FIP Development Goal 11 Education & Workforce Element 

Globally, we will have: 

Evidence of the impact of the pharmaceutical workforce within health systems and health improvement.

Mechanisms 

• Engagement with systems to measure the impact of the pharmaceutical workforce on health improvement and healthcare outcomes. Links with needs-based education, training and workforce planning.
• Gather continuous data points to monitor the performance of the pharmaceutical workforce.
• Ideally, this should be linked with strategies to enhance workforce intelligence.

FIP Development Goal 10 Practice Element 

Globally, we will have: 

Evidence of the impact of pharmaceutical services in terms of health outcomes and quality of life, improved efficiency of health systems and sustainability.

Mechanisms 

• Recognise, assess and take accountability for the societal impact of pharmaceutical services in terms of health outcomes and quality of life, improved efficiency and resilience of health systems, availability and accessibility of services, equity and equitability, and overall sustainability (economic, organisational and environmental).
• Implement systems to measure and monitor service impact and outcomes that are based on agreed definitions and standards, quality and performance indicators, real-world outcomes metrics (including public and patient-reported outcomes) and other data and service assessment intelligence for all professional services, from essential to advanced and specialised.
• Enable and promote practice-based research, health impact assessment and evaluation mechanisms that facilitate practitioner-led evidence generation.
• Implement systems to measure cost effectiveness, including cost-effectivity analysis, cost-benefit and cost–utility analysis, and budgetary impact of pharmacists’ professional services.
• Promote the transparent and rigorous exchange and publication of impact assessment data for pharmaceutical services to inform practice development, policy and funding strategies at local, national and international level.

FIP Development Goal 11 Science Element 

Globally, we will have: 

Strategies and programmes in place to enable timely access to safe, effective, and affordable medical products.

Mechanisms 

• Monitor and report on the positive and negative consequences of new medical products.
• Use of transparent evaluation processes to establish value of outcomes of pharmacy practice service delivered or pharmaceutical science outcomes delivered.
• Promote scientific research to continuously improve patient care using innovative technologies.
• Disseminate the contributions of pharmaceutical sciences underpinning sustained success in drug discovery, development, and utilisation.